Budget 2026 | Biopharma SHAKTI: The scheme sits at the intersection of public health imperatives and industrial policy.
The industry has learned how the ball bounces—now it must decide where to play next. | While 2025 was dedicated to “understanding a little bit more about the rules of this game that we’re playing,” ...
Finance Minister Nirmala Sitharaman announces Biopharma Shakti, a ₹10,000 crore plan to boost biologics, biosimilars, ...
Industry leaders have said the Union Budget 2026 has laid the groundwork for a major shift in India's pharmaceutical sector, with the Biopharma SHAKTI initiative expected to reduce reliance on ...
The Finance Minister has envisioned Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) with an outlay of ₹ 10,000 crores over the next 5 years.
While policy shifts and leadership shakeups at institutions like the Food and Drug Administration dominated headlines in 2025, drugmakers would do well to sift through the noise and remain focused on ...
In a major push for innovation-driven healthcare manufacturing, Finance Minister Nirmala Sitharaman on Sunday announced Biopharma SHAKTI in the union Budget 2026–27, with a financial outlay of Rs ...
Symbolic milestone for new buffer media station: Rentschler Biopharma underscores its commitment to the Laupheim headquarters and to the future of Germany and Europe as leading biotechnology hubs ...
In a major push for innovation-driven healthcare manufacturing, Finance Minister Nirmala Sitharaman on Sunday announced Biopharma SHAKTI in the union Budget 2026–27, with a financial outlay of Rs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results